CU20140132A7 - Métodos de quelatos de oligonucleótidos - Google Patents

Métodos de quelatos de oligonucleótidos

Info

Publication number
CU20140132A7
CU20140132A7 CU2014000132A CU20140132A CU20140132A7 CU 20140132 A7 CU20140132 A7 CU 20140132A7 CU 2014000132 A CU2014000132 A CU 2014000132A CU 20140132 A CU20140132 A CU 20140132A CU 20140132 A7 CU20140132 A7 CU 20140132A7
Authority
CU
Cuba
Prior art keywords
chelates
oligonucleotide
methods
hypertriglyceridemia
hypercholesterolemia
Prior art date
Application number
CU2014000132A
Other languages
English (en)
Inventor
Michel Bazinet
Andrew Vaillant
Original Assignee
Replicor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Replicor Inc filed Critical Replicor Inc
Publication of CU20140132A7 publication Critical patent/CU20140132A7/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

Se describen composiciones farmacéuticas y métodos para el tratamiento de infecciones virales, hipercolesterolemia, hipertrigliceridemia, Alzheimer, enfermedades causadas por priones y distrofia muscular de Duchenne con quelatos de oligonucleótidos.
CU2014000132A 2012-05-18 2014-11-17 Métodos de quelatos de oligonucleótidos CU20140132A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261648694P 2012-05-18 2012-05-18
PCT/CA2013/050378 WO2013170385A1 (en) 2012-05-18 2013-05-17 Oligonucleotide chelate complex methods

Publications (1)

Publication Number Publication Date
CU20140132A7 true CU20140132A7 (es) 2015-02-26

Family

ID=49581827

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2014000132A CU20140132A7 (es) 2012-05-18 2014-11-17 Métodos de quelatos de oligonucleótidos

Country Status (37)

Country Link
US (1) US9616083B2 (es)
EP (1) EP2849760B1 (es)
JP (2) JP6294308B2 (es)
KR (1) KR101975915B1 (es)
CN (1) CN104379152B (es)
AR (1) AR091065A1 (es)
AU (1) AU2013262415B2 (es)
BR (1) BR112014028568B1 (es)
CA (1) CA2873526C (es)
CL (1) CL2014003135A1 (es)
CO (1) CO7131388A2 (es)
CR (1) CR20140522A (es)
CU (1) CU20140132A7 (es)
CY (1) CY1122856T1 (es)
DK (1) DK2849760T3 (es)
DO (1) DOP2014000263A (es)
EA (1) EA034799B1 (es)
EC (1) ECSP14027542A (es)
ES (1) ES2767333T3 (es)
HR (1) HRP20200045T1 (es)
HU (1) HUE047456T2 (es)
IL (1) IL235402B (es)
IN (1) IN2014DN08982A (es)
LT (1) LT2849760T (es)
MX (1) MX360626B (es)
MY (1) MY168209A (es)
NZ (1) NZ701931A (es)
PH (1) PH12014502484B1 (es)
PL (1) PL2849760T3 (es)
PT (1) PT2849760T (es)
RS (1) RS59914B1 (es)
SG (1) SG11201407261XA (es)
SI (1) SI2849760T1 (es)
SM (1) SMT202000025T1 (es)
TW (1) TWI648288B (es)
WO (1) WO2013170385A1 (es)
ZA (1) ZA201408082B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2203173B1 (en) 2007-10-26 2015-12-23 Academisch Ziekenhuis Leiden Means and methods for counteracting muscle disorders
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
CN118581086A (zh) 2012-01-27 2024-09-03 比奥马林技术公司 用于治疗杜兴型肌营养不良症和贝克型肌营养不良症的具有改善特性的rna调节性寡核苷酸
EP2890403A4 (en) 2012-08-30 2016-03-09 Replicor Inc METHOD FOR THE TREATMENT OF HEPATITIS B AND HEPATITIS D INFECTIONS
RS64833B1 (sr) * 2014-07-10 2023-12-29 Replicor Inc Helatni fosforotioatni polimeri nukleinske kiseline za upotrebu u kombinaciji sa inhibitorom hbv polimeraze za lečenje virusnih infekcija hepatitisa b i hepatitisa d
CN113564168B (zh) 2015-04-23 2024-10-25 美国杰龙生物医药公司 使用多价阳离子盐组合物制备多核苷酸的方法
AU2016344609B2 (en) 2015-10-28 2022-05-12 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of duchenne muscular dystrophy
SG10202008046UA (en) * 2015-12-23 2020-09-29 Univ Queensland Technology Nucleic acid oligomers and uses therefor
US20180028554A1 (en) * 2016-07-05 2018-02-01 Biomarin Technologies B.V. Oligomers Having Bicyclic Scaffold Moeities
US11166976B2 (en) 2018-11-08 2021-11-09 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
WO2022229350A2 (en) 2021-04-30 2022-11-03 Tirmed Pharma Ab Single-stranded oligonucleotides for use in the medical treatment and/or prophylaxis of virus infections

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994022488A1 (en) * 1993-04-01 1994-10-13 Isis Pharmaceuticals, Inc. ANTISENSE OLIGOS WHICH INTERFERE WITH mRNA CAP ACTIVITY AND INHIBIT TRANSLATION
US20020166764A1 (en) 1997-08-12 2002-11-14 University Of Southern California Electrochemical sensor devices and methods for fast, reliable, and sensitive detection and quantitation of analytes
US20050020525A1 (en) * 2002-02-20 2005-01-27 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
JP2005538186A (ja) * 2002-09-13 2005-12-15 レプリコール インコーポレーティッド 非配列相補性の抗ウイルス性オリゴヌクレオチド
CN1694959A (zh) * 2002-09-13 2005-11-09 雷普利瑟公司 非序列互补的抗病毒寡核苷酸
WO2006042418A1 (en) 2004-10-19 2006-04-27 Replicor Inc. Antiviral oligonucleotides
WO2007036016A1 (en) 2005-09-29 2007-04-05 Replicor Inc. Therapeutic molecules and their uses
JP2010500290A (ja) * 2006-08-04 2010-01-07 アイシス ファーマシューティカルズ， インコーポレーテッド Ｊｎｋタンパク質を調節するための組成物および方法
WO2009065181A1 (en) * 2007-11-21 2009-05-28 Apollo Life Sciences Limited Nanostructures suitable for delivery of agents
EP2268811A1 (en) * 2008-03-07 2011-01-05 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
US9107933B2 (en) 2009-03-16 2015-08-18 Isis Pharmaceuticals, Inc. Compositions and methods of targeting apolipoprotein B for the reduction of apolipoprotein C-III
CA2764683A1 (en) * 2009-05-28 2010-12-02 Joseph Collard Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
KR20150039873A (ko) 2010-08-20 2015-04-13 레플리코르 인코포레이티드 올리고뉴클레오타이드 킬레이트 복합체

Also Published As

Publication number Publication date
MX2014013885A (es) 2015-05-08
PH12014502484B1 (en) 2021-03-31
JP2015517503A (ja) 2015-06-22
US9616083B2 (en) 2017-04-11
RS59914B1 (sr) 2020-03-31
EP2849760A1 (en) 2015-03-25
JP6294308B2 (ja) 2018-03-14
DK2849760T3 (da) 2020-02-03
CN104379152A (zh) 2015-02-25
CO7131388A2 (es) 2014-12-01
HRP20200045T1 (hr) 2020-03-20
MX360626B (es) 2018-11-12
JP2018058853A (ja) 2018-04-12
TWI648288B (zh) 2019-01-21
ES2767333T3 (es) 2020-06-17
EA034799B1 (ru) 2020-03-23
IL235402A0 (en) 2014-12-31
CA2873526C (en) 2020-08-18
PT2849760T (pt) 2020-01-24
WO2013170385A1 (en) 2013-11-21
MY168209A (en) 2018-10-15
ZA201408082B (en) 2015-12-23
US20130310445A1 (en) 2013-11-21
IN2014DN08982A (es) 2015-05-22
AU2013262415B2 (en) 2017-06-22
CR20140522A (es) 2014-12-10
TW201408689A (zh) 2014-03-01
SI2849760T1 (sl) 2020-03-31
ECSP14027542A (es) 2015-12-31
PH12014502484A1 (en) 2015-01-12
CA2873526A1 (en) 2013-11-21
KR20150016330A (ko) 2015-02-11
IL235402B (en) 2022-01-01
EP2849760B1 (en) 2019-10-30
AU2013262415A1 (en) 2014-11-27
AR091065A1 (es) 2014-12-30
CN104379152B (zh) 2018-10-30
KR101975915B1 (ko) 2019-05-08
CL2014003135A1 (es) 2015-01-09
CY1122856T1 (el) 2021-05-05
HUE047456T2 (hu) 2020-04-28
PL2849760T3 (pl) 2020-05-18
SMT202000025T1 (it) 2020-03-13
NZ701931A (en) 2016-06-24
EA201401276A1 (ru) 2015-04-30
SG11201407261XA (en) 2014-12-30
LT2849760T (lt) 2020-04-10
HK1206259A1 (en) 2016-01-08
EP2849760A4 (en) 2015-03-25
BR112014028568A2 (pt) 2020-06-02
DOP2014000263A (es) 2015-01-31
BR112014028568B1 (pt) 2022-02-15

Similar Documents

Publication Publication Date Title
DOP2014000263A (es) Métodos de quelatos de oligonucleótidos
CL2015001358A1 (es) Potenciadores del cftr deuterados
PH12016500486A1 (en) Aza-pyridone compounds and uses thereof
LT3470063T (lt) Farmacinės kompozicijos, skirtos cftr nulemtų ligų gydymui
BR112015022674A2 (pt) inibidores de bromodomínio
MD4589B1 (ro) Compoziţie farmaceutică cu conţinut de sofosbuvir şi utilizarea acesteia în tratamentul hepatitei virale C
BR112015002524A2 (pt) derivados de alquilpirimidina para o tratamento de infecções virais e outras doenças.
CL2015000942A1 (es) Compuestos de benceno sustituido.
PH12014501738A1 (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
UY33863A (es) Metodos y medicamentos para el tratamiento de la enfermedad de alzheimer
EA201500383A1 (ru) Производные 1,2,4-триазина для лечения вирусных инфекций
PH12016500492B1 (en) Pyridazinone compounds and uses thereof
EP2841107A4 (en) CYTOTOXIC ACTIVITIES DISPOSED OF HIV RELEASING MOLECULES (CDM-HS), CYTOTOXIC EFFECT AGAINST HUMAN IMMUNE WEAKAGE VIRUS AND METHOD OF USE
CL2014001838A1 (es) Compuestos derivados de fluormetil-5,6-dihidro-4h-[1,3]oxazin-2-ilamina, como inhibidores de la bace1; su proceso de obtencion; composicion farmaceutica que los contiene; y su uso para el tratamiento terapeutico y/o profilactico de la enfermedad de alzheimer, esclerosis lateral amiotrofica, cancer, enfermedades cardiovasculares y enfermedades gastrointestinales, entre otras.
BR112014027981A2 (pt) compostos do tipo fumagilol e métodos de produção e utilização dos mesmos
LT2939665T (lt) Farmacinė kompozicija, skirta živ infekcijų gydymui
EA201991196A1 (ru) Претерпевшие самосборку диблок-сополимеры, состоящие из pegmema и несущих лекарственное средство полимерных сегментов
TR201905218T4 (tr) Nörodejenerati̇f hastaliklarin tedavi̇si̇ i̇çi̇n yararli vi̇tanoli̇dler.
BR112015016033A2 (pt) composições e métodos para tratamento de infecções por bactérias
CL2015003431A1 (es) Derivados de piridona para el tratamiento de infecciones virales y enfermedades adicionales
BR112015006220A2 (pt) agentes antibacterianos de tetrahidroquinolina tricíclica
EA201591192A1 (ru) Антибактериальные соединения
MX360040B (es) Nuevo agente antibacteriano derivado de florfenicol unido a sulfoximina y el uso del mismo en el tratamiento de infecciones bacterianas en ganado vacuno.
BR112014009217A2 (pt) antibacterianos à base de fenicol
CL2012001964A1 (es) Uso de compuestos multiciclicos seleccionados de ingenoles, lanosta-8,24-dien-3-oles y sus mezclas para la produccion de composiciones farmaceuticas para la prevencion o tratamiento de infecciones de vih.